ArticleArchives of Razi Institute2025
Article in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Toxin to Therapy: Biomedical Applications of Bee Venom in Cancer, Diabetes, and Neurodegenerative Disorders.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colitis-associated colorectal cancer (CAC) is a serious condition driven by chronic inflammation in the colon, representing a significant challenge in both preventative and therapeutic contexts. Apis mellifera intermissa venom has shown promising therapeutic potential in various disease models, particularly those involving inflammation and tumorigenesis. This study evaluates the therapeutic effects of venom derived from honeybees native to Algeria on the progression of CAC in azoxymethane (AOM)-treated mice. A total of 28 male mice were randomly allocated into four groups (n=7 per group): a control group received a tap drinking water, an AOM group (10 mg AOM /kg body weight), a bee venom group (0.76 mg/kg body weight), and a combined bee venom + AOM group. CAC was induced in mice by a single intraperitoneal injection (i.p) of AOM, and a high-fat diet (45% fat by diet weight) for two weeks. The potential therapeutic effect was evaluated by administering bee venom intraperitoneally on a daily basis for two weeks. AOM significantly reduced body weight, food and water intake while increasing colon weight. Hematological analysis revealed significant reductions in red blood cells (RBC), hemoglobin (HGB), and hematocrit (HCT), coupled with increased white blood cell counts, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH). Elevated serum C-reactive protein (CRP) levels further confirmed systemic inflammation. Macroscopic examination and histopathological analyses of the colon revealed extensive pathological changes in the AOM group, including severe mucosal inflammation, necrotic epithelial damage, and substantial immune cell infiltration. Noteworthy, co-treatment with bee venom effectively mitigated these pathological alterations. Bee venom significantly restored hematological profiles by improving RBC count, HGB, and HCT levels while reducing the elevated WBC count, MCV, and MCH values. CRP levels were significantly reduced, reflecting the anti-inflammatory effects of the venom. Also, macroscopic evaluations demonstrated the preservation of colon morphology, while histopathological assessments revealed an improved epithelial integrity with fewer signs of necrosis and cellular atypia. These findings suggest that Apis mellifera intermissa venom holds potential as an adjunct therapeutic agent for suppressing CAC progression, warranting further investigation into its underlying mechanisms and clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.